UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate to Switzerland’s LimmaTech Biologics for further development and commercialization. This strategic move builds upon GSK’s acquisition of LimmaTech’s predecessor company, GlycoVaxyn, in 2015, which included the vaccine in its portfolio.
Phase I/II Development and Multivalent Immunization Design
The vaccine candidate is currently in Phase I/II of development, targeting 9-month-old infants. The quadrivalent formulation was developed in response to encouraging results from a monovalent version and includes the four most epidemiologically relevant Shigella strains. This multivalent approach aims to provide broad protection against shigellosis, a bacterial infection that poses significant health challenges, particularly in young children.
Collaboration for Vaccine Advancement
The collaboration between GlaxoSmithKline and LimmaTech Biologics highlights the ongoing commitment to advancing vaccine development for infectious diseases. By leveraging LimmaTech’s expertise in further development and commercialization, the partnership aims to bring this crucial vaccine to market, potentially saving lives and improving global health outcomes.-Fineline Info & Tech
